Savaysa
Savaysa Uses, Dosage, Side Effects, Food Interaction and all others data.
Savaysa is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and drug-food interactions. This has prompted enthusiasm for newer agents such as dabigatran, apixaban, and rivaroxaban for effective clot prevention. In addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will be on lifelong therapy.
Administration of edoxaban results in prolongation of clotting time tests such as aPTT (activated partial thromboplastin time), PT (prothrombin time), and INR (international normalized ratio).
| Trade Name | Savaysa |
| Availability | Prescription only |
| Generic | Edoxaban |
| Edoxaban Other Names | Edoxaban |
| Related Drugs | aspirin, propranolol, Xarelto, Eliquis, warfarin, diltiazem, digoxin, enoxaparin, apixaban, rivaroxaban |
| Weight | 15mg, 30mg, 60mg, |
| Type | Oral tablet |
| Formula | C24H30ClN7O4S |
| Weight | Average: 548.06 Monoisotopic: 547.1768513 |
| Protein binding | In vitro plasma protein binding is ~55%. |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States, |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Savaysa is a novel oral anticoagulant used for reducing the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF).
Savaysa is indicated for reducing the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). However, it should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg). It is also indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant.
Savaysa is also used to associated treatment for these conditions: Deep Vein Thrombosis, Pulmonary Embolism, Stroke, Systemic Embolism
How Savaysa works
Savaysa is a selective inhibitor of factor Xa, a serine endopeptidase of the clotting cascade required for cleavage of prothrombin into thrombin.
Toxicity
Premature discontinuation of any oral anticoagulant, including edoxaban, in the absence of adequate alternative anticoagulation increases the risk of ischemic events. If edoxaban is discontinued for reasons other than pathological bleeding or completion of a course of therapy, consider the use of another anticoagulant. Savaysa increases the risk of potentially fatal major bleeding such as intracranial hemorrhage and gastrointestinal bleeding. Patients should be educated on how to watch for signs of major and minor bleeding and when to seek medical help. Co-administration of other anti-coagulants, anti-platelets, or thrombolytics may increase the risk of bleeding and should therefore be avoided.
Food Interaction
- Avoid herbs and supplements with anticoagulant/antiplatelet activity. Additive anticoagulant activity may increase the risk of bleeding. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.
- Take with or without food.
Savaysa Drug Interaction
Major: dabigatranUnknown: ubiquinone, multivitamin, sacubitril / valsartan, ethanol, metformin, loperamide, metoprolol, morphine, semaglutide, acetaminophen, budesonide / formoterol, levothyroxine, tramadol, albuterol, sildenafil, cyanocobalamin, pyridoxine, ascorbic acid, cholecalciferol
Savaysa Disease Interaction
Major: bleeding, hepatic impairment, valvular heart diseaseModerate: renal dysfunction
Volume of Distribution
The steady state volume of distribution is 107 L.
Elimination Route
Following oral administration, peak plasma edoxaban concentrations are observed within 1-2 hours. Absolute bioavailability is 62%.
Half Life
The terminal elimination half-life of edoxaban following oral administration is 10 to 14 hours.
Clearance
22 L/hr
Elimination Route
Savaysa is eliminated primarily as unchanged drug in urine. Renal clearance (11 L/hour) accounts for approximately 50% of the total clearance of edoxaban (22 L/hour). Metabolism and biliary/intestinal excretion account for the remaining clearance.
Innovators Monograph
You find simplified version here Savaysa
